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followed by successful engraftment. Grade 2 nausea and grade 1
emesis were seen brieﬂy on day 2 of TMI. Skin erythema, oral
mucositis, esophagitis, and enteritis were not observed. Conclu-
sions:This report demonstrates the feasibility to selectively deliver
myeloablative doses of radiation to bone and marrow using To-
motherapy. Organ doses were substantially lower than those asso-
ciated with standard TBI and predict for the potential to signiﬁ-
cantly reduce associated toxicities, allowing for dose escalation.
Ongoing trials will deﬁne the maximum TMI/TMLI doses achiev-
able and deﬁne the potential advantages and limitations of this new
approach for patients undergoing HSCT (Table1).
Median Organ Doses (Gy) for TMI 12 and 20 Gy vs Standard TBI
12 Gy in a 20 Year Old Patient with AML
Organ TMI 12 Gy TMI 20 Gy Standard TBI 12 Gy
Lungs 4.3 6.8 8.8
Esophagus 3.9 5.6 12.4
Liver 6.0 8.7 12.3
Kidneys 5.6 8.7 12.2
Bowel 3.5 5.0 12.3
Bladder 7.0 7.4 12.4
Eyes 6.6 7.0 11.3
Parotids 3.9 4.8 11.8
Oral cavity 2.2 3.0 11.8
Stomach 3.1 5.0 12.2
Ovaries 4.3 6.0 12.3
Breasts 6.9 8.7 11.5
Heart 6.2 6.4 12.1
Thyroid 3.7 4.9 12.1
Brain 4.0 7.9 12.0
Lens 1.5 1.9 11.3
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ABSOLUTE NUMBER OF TRANSPLANTED CD34 CELLS EXPRESSING
C-MPL (CD110) CORRELATES WITH SPEED OF PLATELET ENGRAFT-
MENT FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION
Sartor, M.M.1, Antonenas, V.2, Garvin, F.2, Bradstock, K.F.2,
Gottlieb, D.J.2 1. Flow Cytometry Unit, Westmead Hospital., Sydney,
NSW, Australia; 2. Sydney Cellular Therapies Laboratory, Westmead
Hospital, Sydney, NSW, Australia.
Recovery of neutrophil numbers after peripheral blood stem cell
transplantation (PBSCT) is closely associated with graft CD34
cell dose. Predicting the speed of platelet recovery is more difﬁcult
but would be of value given that a signiﬁcant minority of patients
experience delayed platelet recovery and bleeding complications
after transplantation. In this study we retrospectively analysed the
graft composition of 29 patients who underwent autologous trans-
plantation, using blood stem cells mobilized with cyclophoshamide
and G-CSF, to assess the utility of c-mpl expression on CD34
cells as a predictor of platelet engraftment (ie, time to platelet
count greater than 20  109/L for 3 consecutive days without the
need for platelet transfusion). Absolute CD34 cells and CD34
subsets expressing c-mpl were enumerated using a published single
platform viable CD34 ﬂow cytometry assay (BMT, 2005). Of the
29 patients 7 required at least 21 days for platelet engraftment.
These patients received a median graft dose of 5.7  104
CD34CD110 cells/kg compared with a median dose of 13.4 
104 cells/kg received by patients who experienced platelet engraft-
ment within 21 days of transplant (P .013). In contrast, there was
no difference in the number of CD34 cells/kg infused (4.0 v 4.9
106/kg for 	 or  21 days for platelet engraftment respectively,
P  .23). There was a poor correlation between the absolute
number of CD34 cells and the number of CD34CD110 cells
in the graft (r2  0.48). Similarly there was no correlation between
the percentage of CD34 cells expressing c-mpl and the speed of
platelet engraftment (8.1 v 5.8%) for 	 or  21 days for platelet
engraftment respectively, P  .39). Patients with 	21 days for
platelet engraftment received platelet transfusions more often than
those with 21 days for platelet engraftment (median 9 v 2 trans-
fusions, P  .001). The absolute number of CD34/CD110
cells/kg infused at time of transplantation appears to be an impor-
tant factor identifying patients at risk of delayed (	21 days) platelet
engraftment. Those with 6  104CD34/CD110cells/kg are at
particularly high risk of delayed platelet engraftment requiring
multiple transfusion after transplantation.
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AMD3100  G-CSF IMPROVES HEMATOPOIETIC PROGENITOR CELL
(HPC) COLLECTION IN PATIENTS WITH HODGKIN’S DISEASE (HD)
Cashen, A.F.1, Devine, S.1, Vij, R.1, DiPersio, J.1 Washington Uni-
versity School of Medicine, St. Louis, MO.
For patients undergoing autologous stem cell transplantation, the
number of CD34 cells infused is a reliable predictor of neutro-
phil and platelet engraftment, with doses 5  106 CD34
cells/kg associated with faster count recovery. However, among the
98 patients with HD who have undergone G-CSF-alone mobili-
zation at our institution in the past 5 years, 22% did not achieve a
minimum HPC collection of 2  106 CD34 cells/kg in 5
apheresis procedures, and only 15% achieved a collection 5 
106 CD34 cells/kg. AMD3100 mobilizes HPCs by reversibly
inhibiting the interaction of CXCR4 and SDF-1
. It has been
shown to improve HPC mobilization in patients with multiple
myeloma and non-Hodgkin’s lymphoma. Here we present results
for the ﬁrst ten HD patients treated with a mobilization regimen of
AMD3100  G-CSF. Ten patients with relapsed (8) or refractory
(2) HD were mobilized with G-CSF (10 ug/kg/day)  AMD3100
(240 ug/kg/day) beginning on day 4. Apheresis was performed 11
hours after each AMD3100 dose. The ﬁrst dose of AMD3100
produced a median (range) 3.0 (1.9–5.1)-fold increase in the num-
ber of circulating CD34 cells. Six patients achieved a collection
of 5  106 CD34 cells/kg, and all patients collected 	2  106
CD34 cells/kg (range, 3.6–9.4). The median (range) number of
apheresis procedures performed per patient was 2 (1–4). No grade
II-IV adverse events were ascribed to AMD3100. All patients have
been transplanted with G-CSF AMD3100 mobilized cells. They
have had prompt and stable engraftment, with median neutrophil
recovery at day9 (9–11) and median platelet recovery at day16
(12–23). We conclude that AMD3100G-CSF is a well-tolerated
and effective mobilization regimen in patients with HD. All pa-
tients (100%, 95% CI 69%–100%) mobilized with AMD3100 
G-CSF achieved the minimum collection of 2  106 CD34
cells/kg, and a signiﬁcantly higher proportion of patients (60%,
95% CI 26%–88%) achieved the goal collection of  5  106
CD34 cells/kg than did the historical controls (15%). Impor-
tantly, the median collection in the ﬁrst two days of pheresis was
5.4  106 CD34 cells/kg, which is signiﬁcantly better than
historical controls, who collected a median 3.0  106 CD34
cells/kg in the ﬁrst two days of pheresis (P  .014). Our results
demonstrate that the mobilization regimen of AMD3100  G-
CSF can improve the number of HPCs collected and decrease the
number of days of pheresis in HD patients.
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HEMATOPOIETIC AC133 STEM CELL THERAPY FOR PATIENTS WITH
SEVERE PERIPHERAL VASCULAR DISEASE
Statkute, L.1, Oyama, Y.1, Pearce, W.1, Yaung, K.1, Villa, M.1,
Shook, T.1, Clifton, R.1, Verda, L.1, Krosnjar, N.1, Burt, R.K.1 Division
of Immunotherapy, Department of Medicine, Northwestern University
Feinberg School of Medicine, Chicago, IL.
Hematopoietic stem cells, especially more primitive endothelial
cell precursors, AC133 cells, may contribute to neo-angiogene-
sis. Here we report short-term outcomes of the ﬁrst 5 patients who
underwent autologous selected AC133 stem cell percutaneous
transplant for their medically refractory and not-amenable to sur-
gical reconstruction lower extremity (LE) peripheral vascular dis-
ease (PVD). Patients were 3 females and 2 males; median age was
59 (range 26–84) years old. Peripheral blood AC133 cells were
mobilized with G-CSF 10 mcg/kg/day for 4 days. Median aphere-
sis number of was 1 (range 1 to 2). AC133 cells were enriched
using CliniMACS device, Miltenyi Biotec, Inc. Total number of
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